Bertrand Huard

List of Publications by Year
in descending order

69 papers	4,510 citations	147801 31 h-index	106344 65 g-index
70 all docs	70 docs citations	70 times ranked	5600 citing authors

#	Article	IF	Citations
1	Plasmocyte depletion in autoimmune diseases. , 2022, , 179-191.		0
2	Further analyses of APRIL/APRIL-receptor/glycosaminoglycan interactions by biochemical assays linked to computational studies. Glycobiology, 2021, 31, 772-786.	2.5	9
3	The number 13 of the family: a proliferation inducing ligand. Current Opinion in Immunology, 2021, 71, 132-137.	5.5	6
4	Case Report: In Situ Expression of a Proliferation-Inducing Ligand in Neuromyelitis Optica. Frontiers in Neurology, 2021, 12, 721877.	2.4	1
5	Polarized Secretion of APRIL by the Tonsil Epithelium Upon Toll-Like Receptor Stimulation. Frontiers in Immunology, 2021, 12, 715724.	4.8	2
6	Advanced Molecular Dynamics Approaches to Model a Tertiary Complex APRIL/TACI with Long Glycosaminoglycans. Biomolecules, 2021, 11, 1349.	4.0	6
7	The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5. Blood Advances, 2021, 5, 4338-4351.	5.2	9
8	Inhibition of Chondroitin Sulfate Proteoglycans by APRIL. Methods in Molecular Biology, 2021, 2248, 43-61.	0.9	2
9	APRIL-producing eosinophils are involved in gastric MALT lymphomagenesis induced by Helicobacter sp infection. Scientific Reports, 2020, 10, 14858.	3.3	15
10	APRIL Induces a Novel Subset of IgA+ Regulatory B Cells That Suppress Inflammation via Expression of IL-10 and PD-L1. Frontiers in Immunology, 2019, 10, 1368.	4.8	63
11	A proliferationâ€inducing ligandâ€“mediated antiâ€inflammatory response of astrocytes in multiple sclerosis. Annals of Neurology, 2019, 85, 406-420.	5.3	32
12	Abundant a proliferation-inducing ligand (APRIL)-producing macrophages contribute to plasma cell accumulation in immunoglobulin G4-related disease. Nephrology Dialysis Transplantation, 2019, 34, 960-969.	0.7	17
13	The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting. Journal of Autoimmunity, 2018, 95, 179-190.	6.5	31
14	Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients. Blood Cancer Journal, 2018, 8, 66.	6.2	24
15	Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. International Reviews of Immunology, 2017, 36, 3-19.	3.3	144
16	Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 1227-1238.	6.1	91
17	CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL. Cancer Research, 2017, 77, 1097-1107.	0.9	59
18	Progression of fibrosis in patients with chronic viral hepatitis is associated with <scp>IL</scp>â€17⁺ neutrophils. Liver International, 2016, 36, 1116-1124.	3.9	30

#	Article	IF	Citations
19	Revisiting IL-6 antagonism in multiple myeloma. Critical Reviews in Oncology/Hematology, 2016, 105, 1-4.	4.4	53
20	Pathogenic Role of a Proliferation-Inducing Ligand (APRIL) in Murine IgA Nephropathy. PLoS ONE, 2015, 10, e0137044.	2.5	24
21	FP304ABERRANT APRIL EXPRESSION IN TONSILLAR GERMINAL CENTER B CELLS IN IGA NEPHROPATHY PATIENTS. Nephrology Dialysis Transplantation, 2015, 30, iii168-iii169.	0.7	0
22	No Evidence That Soluble TACI Induces Signalling via Membrane-Expressed BAFF and APRIL in Myeloid Cells. PLoS ONE, 2013, 8, e61350.	2.5	27
23	Selective APRIL Blockade Delays Systemic Lupus Erythematosus in Mouse. PLoS ONE, 2012, 7, e31837.	2.5	33
24	A Novel Mouse Model for Multiple Myeloma (MOPC315.BM) That Allows Noninvasive Spatiotemporal Detection of Osteolytic Disease. PLoS ONE, 2012, 7, e51892.	2.5	61
25	Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. Blood, 2011, 118, 1838-1844.	1.4	85
26	Evidence for a Repertoire of Functional Untolerized CD4⁺ T Cells Specific for Melanomaâ€Associated Antigens. Scandinavian Journal of Immunology, 2011, 74, 80-86.	2.7	3
27	Absence of up-regulation for a proliferation-inducing ligand in Sjogren's sialadenitis lesions. Rheumatology, 2011, 50, 1211-1215.	1.9	10
28	CD56^{bright} NK cells after hematopoietic stem cell transplantation are activated mature NK cells that expand in patients with low numbers of T cells. European Journal of Immunology, 2010, 40, 3246-3254.	2.9	31
29	Buffy's, B cells, and membrane BAFF. Arthritis and Rheumatism, 2010, 62, 1557-1558.	6.7	1
30	Comment on â€œCutting Edge: FcR-Like 6 Is an MHC Class II Receptorâ€ Journal of Immunology, 2010, 185, 4965.1-4965.	0.8	0
31	Comment on â€œDendritic Cells and Monocyte/Macrophages That Create the IL-6/APRIL-Rich Lymph Node Microenvironment Where Plasmablasts Matureâ€ FIGURE 1.. Journal of Immunology, 2009, 182, 5159-5159.	0.8	1
32	Tumors that look for their springtime in APRIL. Critical Reviews in Oncology/Hematology, 2009, 72, 91-97.	4.4	26
33	Lymph node tumor metastases: more susceptible than primary tumors to CD8+ T-cell immune destruction. Trends in Immunology, 2009, 30, 569-573.	6.8	11
34	Synovial tissues concentrate secreted APRIL. Arthritis Research and Therapy, 2009, 11, R144.	3.5	29
35	Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Seminars in Immunopathology, 2008, 30, 425-437.	6.1	210
36	Role of the tumor necrosis factor ligand APRIL in Hodgkin's lymphoma: a retrospective study including 107 cases. Experimental Hematology, 2008, 36, 533-534.	0.4	5

#	Article	IF	Citations
37	Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas. European Journal of Cancer, 2008, 44, 2097-2100.	2.8	22
38	Direct Presentation of a Melanocyte-Associated Antigen in Peripheral Lymph Nodes Induces Cytotoxic CD8+ T Cells. Cancer Research, 2008, 68, 8410-8418.	0.9	12
39	APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood, 2008, 111, 2755-2764.	1.4	311
40	Heparan sulfate proteoglycans, Fc receptors, and DC suppression. Blood, 2008, 112, 915-916.	1.4	3
41	APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. Journal of Clinical Investigation, 2008, 118, 2887-95.	8.2	175
42	Extralymphatic Tumors Prepare Draining Lymph Nodes to Invasion via a T-Cell Cross-Tolerance Process. Cancer Research, 2007, 67, 5009-5016.	0.9	39
43	Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood, 2007, 109, 331-338.	1.4	138
44	Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells. Melanoma Research, 2007, 17, 169-176.	1.2	21
45	HLA and KIR polymorphisms affect NK-cell anti-tumor activity. Trends in Immunology, 2007, 28, 437-441.	6.8	32
46	Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin's Disease. Leukemia, 2007, 21, 1324-1327.	7.2	32
47	T cell tolerance to the skin: a central role for central tolerance. Seminars in Immunopathology, 2007, 29, 59-64.	6.1	0
48	A CD40â€“CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. Journal of Molecular Medicine, 2006, 84, 785-797.	3.9	17
49	The source of APRIL up-regulation in human solid tumor lesions. Journal of Leukocyte Biology, 2006, 80, 697-704.	3.3	68
50	Tumor-Infiltrating Dendritic Cells Are Potent Antigen-Presenting Cells Able to Activate T Cells and Mediate Tumor Rejection. Journal of Immunology, 2006, 176, 61-67.	0.8	84
51	Impaired CD40L signaling is a cause of defective IL-12 and TNF-Î± production in Sezary syndrome: circumvention by hexameric soluble CD40L. Blood, 2005, 105, 219-225.	1.4	36
52	Identification of proteoglycans as the APRIL-specific binding partners. Journal of Experimental Medicine, 2005, 201, 1375-1383.	8.5	323
53	BAFF production by antigen-presenting cells provides T cell co-stimulation. International Immunology, 2004, 16, 467-475.	4.0	134
54	Expression of inhibitory KIR is confined to CD8+ effector T?cells and limits their proliferative capacity. European Journal of Immunology, 2004, 34, 3413-3422.	2.9	39

#	Article	IF	Citations
55	Activating CD94:NKG2C and inhibitory CD94:NKG2A receptors are expressed by distinct subsets of committed CD8+ TCR ?? lymphocytes. European Journal of Immunology, 2004, 34, 3456-3464.	2.9	58
56	Selective Expression of FLIP in Malignant Melanocytic Skin Lesions. Journal of Investigative Dermatology, 2001, 117, 360-364.	0.7	97
57	KIR down-regulation on NK cells is associated with down-regulation of activating receptors and NK cell inactivation. European Journal of Immunology, 2001, 31, 1728-1735.	2.9	24
58	T Cell Costimulation by the TNF Ligand BAFF. Journal of Immunology, 2001, 167, 6225-6231.	0.8	198
59	A role for MHC class I down-regulation in NK cell lysis of herpes virus-infected cells. European Journal of Immunology, 2000, 30, 509-515.	2.9	89
60	A subpopulation of CD8+ T cells specific for melanocyte differentiation antigens expresses killer inhibitory receptors (KIR) in healthy donors: evidence for a role of KIR in the control of peripheral tolerance. European Journal of Immunology, 2000, 30, 1665-1675.	2.9	40
61	KIR expression on self-reactive CD8+ T cells is controlled by T-cell receptor engagement. Nature, 2000, 403, 325-328.	27.8	121
62	A role for MHC class I down-regulation in NK cell lysis of herpes virus-infected cells. European Journal of Immunology, 2000, 30, 509-515.	2.9	2
63	Expression of Inhibitory Receptors for MHC Class I Molecules on T Cells. Critical Reviews in Immunology, 2000, 20, 6.	0.5	2
64	LAG-3 does not define a specific mode of natural killing in human. Immunology Letters, 1998, 61, 109-112.	2.5	73
65	Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 5744-5749.	7.1	224
66	T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding. European Journal of Immunology, 1996, 26, 1180-1186.	2.9	115
67	CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. European Journal of Immunology, 1995, 25, 2718-2721.	2.9	308
68	Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. European Journal of Immunology, 1994, 24, 3216-3221.	2.9	189
69	Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.. Journal of Experimental Medicine, 1992, 176, 327-337.	8.5	331